Orsight Pharma develops a breakthrough small molecule treatment designed to preserve vision and prevent blindness through a novel VEGF-independent mechanism. This drug offers a ray of hope, especially for those who have not seen satisfactory results with existing treatments. The company's product not only stands to benefit patients unresponsive to current therapies but also has the potential to enhance visual outcomes when used in combination with them.